Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia

NCT02674763 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: IMGN779

Sponsor

ImmunoGen, Inc.